Inhalable aerosol medicament for the treatment or prevention of pain

• US 20050180926A1
• Filed: 04/18/2005
• Published: 08/18/2005
• Est. Priority Date: 08/03/2000
• Status: Abandoned Application

• Current Assignee: Air Liquide Sante International (L'Air Liquide SA)
• Original Assignee: Air Liquide Sante International (L'Air Liquide SA)
• Inventors: Lescure, Franck, Lemaire, Marc, Lecourt, Laurent
• Application Number:
  US11/107,809
• Publication Number:
  US 20050180926A1
• Time in Patent Office: Days
• US Class Current: 424/46
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0073 Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M
• CPC Class Codes: A61K 9/008 comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
• CPC Class Codes: A61K 9/124 characterised by the propellant
• CPC Class Codes: A61P 23/00 Anaesthetics
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention concerns the use of at least one gas in combination with at least one active product for manufacturing an inhalable medicament or part of an inhalable medicament intended for the treatment or prevention of pain in humans or animals. The gas is chosen from among helim, oxygen, nitrogen, xenon, hydrogen, carbon monoxide (CO), carbon dioxide (CO₂), argon, krypton, nitrogen monoxide (NO), nitrogen protoxide (N₂O), carbonated hydrocarbons, fluorocarbons and mixtures of several of these gases. The active product is chosen from among paracetamol, acetylsalicylic acid, arylcarboxylic acid, corticosteroids, mineralosteroids, non-steoroidal anti-inflammatory drugs and their derivatives, codeine and its derivatives, morphine and morphine mimetics.

Claims

1. A method for manufacturing an inhalable medicament or part of an inhalable medicament for the treatment or prevention of pain in humans or animals comprising:

combining gaseous xenon in combination with at least one active product chosen from among paracetamol, acetylsalicylic acid, arylcarboxylic acid, corticosteroids, mineralosteroids, non-steroidal anti-inflammatory drugs and their derivatives, codeine and its derivatives, morphine and morphine mimetics.

2. A method according to claim 1, wherein the active product is chosen from among analgesics.

3. A method according to claim 1, wherein the active product is chosen from among compounds with an anti-inflammatory action.

4. A method according to claim 1, wherein the active product is chosen from among antipyretics.

5. A method according to claim 1, wherein the medicament further contains at least one additional gas chosen from among helium, oxygen, nitrogen, hydrogen, carbon monoxide (CO), carbon dioxide (CO.sub.2), argon, krypton, nitrogen monoxide (NO), nitrogen protoxide (N.sub.2O), carbonated hydrocarbons, fluorocarbons and mixtures of several of these gases.

6. A method according to claim 1, wherein the inhalable medicament is in the form of an aerosol comprising xenon and said active product in the form of a powder, liquid or a powder/liquid mixture.

7. A method according to claim 1, wherein the inhalable medicament contains a therapeutically effective quantity of active product.

8. A method according to claim 1, in which the combination of xenon with said at least one active product leads to a synergistic effect.

9. The method according to claim 1, in which the inhalable medicament contains at least one gas chosen from CO and NO, preferably a gas mixture containing NO and CO, and at least one active product with an anti-inflammatory action.

10. The method according to claim 1, in which the inhalable medicament contains at least one gas chosen from O.sub.2 and N.sub.2O.

11. The method according to claim 1, in which the inhalable medicament contains O.sub.2 and N.sub.2O, and at least one active product with an analgesic or morphine-like action.

12. Inhalable medicament formed by a combination of at least xenon and at least one active product with an analgesic action, said active product being chosen from among paracetamol, acetylsalicylic acid, arylcarboxylic acid, corticosteroids, mineralosteroids, non-steroidal anti-inflammatory drugs and their derivatives, codeine and its derivatives, morphine and morphine mimetics.

13. Medicament according to claim 12, further comprising at least one additional gas chosen from among helium, oxygen, nitrogen, hydrogen, carbon monoxide (CO), carbon dioxide (CO.sub.2), argon, krypton, nitrogen monoxide (NO), nitrogen protoxide (N.sub.2O), carbonated hydrocarbons, fluorocarbons and mixtures of several of these gases.

14. Medicament according to claim 12, characterized in that it contains a therapeutically effective amount of active product.

15. A method for treatment or prevention of pain in humans or animals comprising the step of administrating by inhalation an inhalable medicament formed by a combination of at least xenon and at least one active product with an analgesic action, said active product being chosen from among paracetamol, acetylsalicylic acid, arylcarboxylic acid, corticosteroids, mineralosteroids, non-steroidal anti-inflammatory drugs and their derivatives, codeine and its derivatives, morphine and morphine mimetics.

16. A method according to claim 15, wherein the inhalable medicament further comprises at least one additional gas chosen from among helium, oxygen, nitrogen, hydrogen, carbon monoxide (CO), carbon dioxide (CO.sub.2), argon, krypton, nitrogen monoxide (NO), nitrogen protoxide (N.sub.2O), carbonated hydrocarbons, fluorocarbons and mixtures of several of these gases.

17. Method according to claim 15, wherein the inhalable medicament contains a therapeutically effective amount of active product.

18. Method according to claim 15, wherein the active product is chosen from among analgesics.

19. Method according to claim 15, wherein the active product is chosen from among compounds with an anti-inflammatory action.

20. Method according to claim 15, wherein the active product is chosen from among antipyretics.